470 related articles for article (PubMed ID: 8458605)
1. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
[TBL] [Abstract][Full Text] [Related]
3. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
Léger J; Reynaud R; Czernichow P
J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
[TBL] [Abstract][Full Text] [Related]
4. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
5. Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.
Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
Horm Metab Res; 1992 Mar; 24(3):122-6. PubMed ID: 1533604
[TBL] [Abstract][Full Text] [Related]
6. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
Massart F; Federico G; Harrell JC; Saggese G
Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
[TBL] [Abstract][Full Text] [Related]
7. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
[TBL] [Abstract][Full Text] [Related]
8. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
Bajpai A; Sharma J; Kabra M; Gupta AK; Menon PS
Indian Pediatr; 2002 Jul; 39(7):633-9. PubMed ID: 12147888
[TBL] [Abstract][Full Text] [Related]
9. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
11. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
[TBL] [Abstract][Full Text] [Related]
12. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.
Comite F; Cutler GB; Rivier J; Vale WW; Loriaux DL; Crowley WF
N Engl J Med; 1981 Dec; 305(26):1546-50. PubMed ID: 6458765
[TBL] [Abstract][Full Text] [Related]
13. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
15. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.
Liang Y; Wei H; Zhang J; Hou L; Luo X
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):558-61. PubMed ID: 17219967
[TBL] [Abstract][Full Text] [Related]
17. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature.
Yanovski JA; Rose SR; Municchi G; Pescovitz OH; Hill SC; Cassorla FG; Cutler GB
N Engl J Med; 2003 Mar; 348(10):908-17. PubMed ID: 12621135
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
19. Puberty without gonadotropins. A unique mechanism of sexual development.
Wierman ME; Beardsworth DE; Mansfield MJ; Badger TM; Crawford JD; Crigler JF; Bode HH; Loughlin JS; Kushner DC; Scully RE
N Engl J Med; 1985 Jan; 312(2):65-72. PubMed ID: 3917301
[TBL] [Abstract][Full Text] [Related]
20. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
Lanes R; Gunczler P
Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
